Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo - Top-Institutions - MDSpire

Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

  • By

  • Galina Rodionov

  • Michal Rosenzwaig

  • Michal Schrift Tzadok

  • Moran Kvint

  • Elazar Gevir

  • Elina Zorde-Khvalevsky

  • Amnon Peled

  • Shai Yarkoni

  • Amos Ofer

  • May 10, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Immunotherapy
    • Cellular Therapy

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Immunology
    • Cell Therapy

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunotherapy

  • #4

    Sheba Medical Center
    Sheba Medical Center

    Ramat Gan, Israel

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunotherapy

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunology

Original Source(s)

Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

  • by Galina Rodionov, Michal Rosenzwaig, Michal Schrift Tzadok, Moran Kvint, Elazar Gevir, Elina Zorde-Khvalevsky, Amnon Peled, Shai Yarkoni, Amos Ofer

  • May 10, 2022

Related Content

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.

  • January 9, 2025

  • 1 min
Soluble CD147 in Plasma During Sepsis: Correlation with Disease Severity and Prognostic Implications

Examining Transcriptomic Markers Associated With Neutrophil Extracellular Traps to Predict Mortality Risk in Neonatal Sepsis